Faiq Gorial

Dr. Faiq Gorial


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
FGFaiq Gorial
Faiq Gorial
SMSabeeh Mashhadani
Sabeeh Mashhadani
HSHend M Sayaly
Hend M Sayaly
BDBasim Dhawi Dakhil
Basim Dhawi Dakhil
MAMarwan M. AlMashhadani
Marwan M. AlMashhadani
JRJawad I Rasheed
Jawad I Rasheed
Background: To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect. Objectives: To assess the effectiveness of ivermectin (IVM) as add-on therapy to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of COVID-19. Methods: This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine (HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities. The primary outcome was percentage of cured patients, defined as symptoms free to be discharged from the hospital and 2 consecutive negative PCR test from nasopharyngeal swabs at least 24 hours apart. The secondary outcomes were time to cure in both groups and evaluated by measuring time from admission of the patient to the hospital till discharge. Results: Of 87 patients included in the study,t he mean age ± SD (range) of patients in the IVM group was similar to controls [44.87 ± 10.64 (28-60) vs 45.23 ± 18.47 (8-80) years, p=0.78] Majority of patients in both groups were male but statistically not significant [11(69%) versus 52 (73%), with male: female ratio 2.21 versus 2.7-, p=0.72) All the patients of IVM group were cured compared with the controls [16 (100 %) vs 69 (97.2 %)]. Two patients died in the controls. The mean time to stay in the hospital was significantly lower in IVM group compared with the controls (7.62 ± 2.75 versus 13.22 ±5.90 days, p=0.00005, effect size= 0.82). No adverse events were observed Conclusions: Add-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with controls. however, a larger prospective study with longer follow up may be needed to validate these results.

4 September 2021 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AAAhmed S. Abdulamir
Ahmed S. Abdulamir
FGFaiq Gorial
Faiq Gorial
SSSattar Jabar Saadi
Sattar Jabar Saadi
MMMohammed Fauzi Maulood
Mohammed Fauzi Maulood
HHHashim Ali Hashim
Hashim Ali Hashim
MAManal K. Abdulrrazaq
Manal K. Abdulrrazaq
COVID-19 pandemic has ignited the urge for repurposing old drugs as candidate antiviral medicines to treat novel challenges of viral infections. Niclosamide (NCS) is an anti-parasitic drug of known antiviral potential. Therefore, this study attempts to investigate the antiviral effect and safety of NCS on SARS-CoV-2 caused COVID-19 patients. Randomized controlled open label clinical trial encompassed 75 COVID-19 patients treated with standard of care plus NCS were included as experimental group and 75 COVID-19 patients treated with only standard of care therapy as control group. Survival rate, time to recovery, and side effects were the main endpoints for the assessment of the therapeutic effect and safety of NCS. No significant difference between the two study groups in the incidence of death Vs recovery within 30 days of follow up(p = 1).Median survival time to cure in the NCS addon group was significantly less than controls (5 Vs 7days, Log rank p = 0.005).All the recoveries took place within 20 days in the NCS add on group, which is 10 days shorter than that in the controls (30 days), NCS add on treatment increased the risk of cure by 60% per day compared to control group (adjusted HR = 1.6,p = 0,007) after adjusting for the count of comorbidities. Additionally, two or more comorbidities reduced the risk of cure to 33% (p < 0.001).Male gender increased the risk of cure by 42% (p = 0.046). Older age group decreased the risk of recovery per day to 0.58 and 0.53 for 50–59 and 60+ years of age. Hyypertension (HT) and diabetes mellitus (DM) significantly reduced the risk of being cured per day to 0.56 (p = 0.003)and 0.65 (p = 0.039) respectively. No significant signals of safety in NCS add on therapy compared to control group. adding NCS to the standards of care measures increased the risk of the cure and had shorter time to stay in the hospital compared with controls., male gender increased the risk of cure, while older patients>40 years, HT, and DM decreased the risk of cure. Also, NCS add on therapy was relatively safe; hence, NCS is of clinical benefit for freeing hospital beds for more patients in pandemic crisis.

1 June 2020 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
FGFaiq Gorial
Faiq Gorial
MJMais Ajeel Jabbar
Mais Ajeel Jabbar
Behçet's syndrome (BD) is a systemic inflammatory vasculitis of unknown aetiology, affecting vessels of different types, sizes and locations and characterized by recurrent episodes of acute inflammation, including mucocutaneous manifestations (oral aphthous ulcers, genital ulcers and skin lesions) and gastrointestinal, musculoskeletal, neurological, ophthalmic and vascular involvement which lead to a significant morbidity and impaired health related quality of life (HRQoL). Few studies reported impact of disease activity on HRQoL. To assess the impact of BD activity on HRQoL. This cross sectional study included patients with Behçet's disease diagnosed according to the International Study Group criteria 1990 for BD. Age of the patients, sex, smoking status, educational level, disease duration, organ involvement, age at disease onset, and medications used were recorded. Behçet's Disease Disease activity was assessed using Behçet's Disease Current Activity Form (BDCAF) and HRQoL was evaluated using The Short Form-36 (SF-36). A total of 71 patients (45 males, 26 females) with Behçet's disease were enrolled in this study. Mean age of patients was 36.0 ± 10.8 years, Males represented the majority of patients (63.4%). BDCAF was significantly and negatively correlated with total SF-36 score (standardized β = - 0.520, p < 0.0001). The mean BDCAF was significantly more in females compared to males (6.154 ± 2.444 vs 4.467 ± 2.785, p = 0.012). While the mean SF36 was significantly more in males compared to females (57.722 ± 21.627 vs 41.435 ± 18.993, p = 0.002). After multiple linear stepwise regression analysis, still BDCAF significantly and negatively affected HRQoL in BD (partial r = -0.255, p = 0.043). Male gender, cyclosporine users, infliximab users, and Adalimumab users had significant positive impact on total SF-36 score (partial r = 0.293, p = 0.020; partial r = 0.256, p- = 0.043, partial r = 0.414; p = 0.00, partial r = 0.399, p = 0.001 respectively). While disease duration, and MMF users (partial r = -0.295, p = 0.019; partial r = -0.250, p = 0.043) had significant negative impact on total SF-36 score, and there was weak positive correlation between vascular involvement and total SF36 score (partial r = 0.244,p = 0.053) and a negative weak correlation between the use of anticoagulant with total SF-36 score (partial r = -0.233, p = 0.066). Behçet's disease activity has a significant negative impact on HRQoL This may suggest that treating activity of disease may improve HRQoL.

18 April 2018 in Mediterranean Journal of Rheumatology
Verified
Journal Article
Open access
ZAZiad Al-Rawi
Ziad Al-Rawi
FGFaiq Gorial
Faiq Gorial
AAAnmar Abdulwahhab Al-Bayati
Anmar Abdulwahhab Al-Bayati
Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease, which affects the joints and other body systems. Red cell distribution width (RDW) is a part of the complete blood count (CBC) test and estimates erythrocytic variability. Objective: To evaluate RDW in RA and to assess the relationships of baseline demographic and clinical characteristics with RDW. Patients and Methods: A total of 111 patients with RA diagnosed according to the 2010 American College of Rheumatology/European League Against Rheumatism (2010 ACR/EULAR) classification criteria for Rheumatoid arthritis) and compared with 97 healthy individuals matched in age and gender as controls. Age, gender, body mass index (BMI), clinical diseases activity index (CDAI) and diseases activity score 28 using erythrocyte sedimentation rate (ESR) (DAS28-ESR), and diseases durations were recorded. Rheumatoid Factor (RF), anti-citrullinated peptide antibody (ACPA), complete blood count (CBC) and ESR were all measured. Results: The mean age for patients and controls were 46.53 ± 11.89 and 48.19 ± 12.06 years respectively (p=0.321). RDW was significantly higher in patients (14.5 ± 2.8%) compared with controls (12.4 ± 1.1 %) (p=>0.001). There was no significant correlation between various variables (age, Body Mass Index (BMI), disease duration, CDAI), DAS28-ESR, ESR, gender, RF, and ACPA) with RDW. The RDW had good ability to differentiate RA patients from controls (AUC=0.804, 95% CI=0.744 – 0.856. p=<0.001), while ESR had excellent ability to differentiate between RA patients and controls (AUC=0.926, 95% CI=0.882 – 0.958, p<0.001). Conclusions: RDW was significantly elevated in RA patients.

1 December 2018 in Mediterranean Journal of Rheumatology
Verified
Journal Article
Open access
FGFaiq Gorial
Faiq Gorial
SSShams Al-Sabah Anwer Sabah
Shams Al-Sabah Anwer Sabah
MKMena Baqer Kadhim
Mena Baqer Kadhim
NJNorhan Badri Jamal
Norhan Badri Jamal
OBJECTIVES: To assess the functional status in a cohort of Iraqi patients with knee Osteoarthritis (OA) and its relation to demographic and clinical features. PATIENTS AND METHODS: This cross-sectional study was conducted on 150 patients with knee OA diagnosed according to the American College of Rheumatology Criteria for classification knee OA. Patients’ age, gender, body mass index (BMI), smoking history, educational level, and disease duration were recorded. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score was used to measure functional status of patients with knee OA. RESULTS: A total of 150 (97 females) patients with knee OA were recruited in the study. The mean age of patients was 52.5±10.1 year and mean BMI was 30.3±6.0 kg/m 2 . The mean of total WOMAC score was 8.05±2.10 (Range 3-12). The mean WOMAC of: pain score was 3.22 ±0.76 (1-4), stiffness score was 2.05±1.01 and for functional disability score was 2.79±0.88. There was a positive significant correlation between age of the patients and severity of knee OA assessed with total WOMAC score (p=0.026). However, there was a significant negative correlation between educational level and total WOMAC score (p=0.015). CONCLUSIONS: Functional status in knee OA was impaired and there was a statistically positive significant correlation between age of the patients and severity of knee OA with functional impairment. Also, significant negative correlation was demonstrated between educational level and functional impairment.

1 October 2022 in Baghdad Science Journal
Verified
Journal Article
Open access
PDF file
NMNoor Ulhuda G. Mohammed
Noor Ulhuda G. Mohammed
FKFayhaa M. Khaleel
Fayhaa M. Khaleel
FGFaiq Gorial
Faiq Gorial
Chitinase-3-like 1 protein (YKL-40) is a glycoprotein primarily produced in the arthritic joint and plays a crucial role in inflammatory processes. The aim of the study is to establish the role of YKL-40 as a biomarker for rheumatoid arthritis (RA) compared to proinflammatory biomarkers and disease activity. The study included 58 patients and 18 control. Diseases activity score (DAS-28) and clinical disease activity index (CDAI) were measured. Serum level of YKL-40, tumor necrosis factor-α (TNF-α), interleukin-1B (IL-1β), erythrocyte sedimentation (ESR), rheumatoid factor (RF), C-reactive protein (CRP), and anti-citrullinated protein antibody (ACPA) were assessed. The results showed that the median serum YKL-40 level which was 5.42 ng/ml, the TNF-a level which was 123.6 ng/ml, and the IL-1B level which was 204.365 pg/dl were significantly higher in patients compared to control 3.28 (1.58–4.99) ng/ml, 56.47 (9.38–77.01) ng/ml and 67.887 (15.493–122.689)pg/dl respectively. There was no correlation between serum YKL-40 and disease activity, while there were significant associations observed with TNF-α (r=0.5,p =0.0001) and IL-1β (r=0.41, p=0.001). YKL-40 indicating good levels of RA prediction at 2.47 ng/ml, sensitivity 87.9%, specificity 58.6%, accuracy 78.1%, PPV 80.9%, and NPV 70.8%. In conclusion, a higher level of serum YKL-40 is found in RA patients. The findings from our study suggest a strong association between YKL-40 and the proinflammatory biomarkers. As a result, these biomarkers together might play a role in RA pathogenesis, and YKL-40 may be used as a potential diagnostic biomarker for RA.